original without the text.png
iStock_000007245036Medium.jpg
shutterstock_193463279.jpg
original without the text.png

Genostics


The future of personalised cancer testing, today.

Find out more

SCROLL DOWN

Genostics


The future of personalised cancer testing, today.

Find out more

Genostics® is an Australian medical diagnostic, education and consultancy company.

In this Genostics podcast, Dr. Joachim Fluhrer and Dr. Katherina Pachmann talk about Circulating Tumour Cells: what they are, their importance, and how to detect them. Dr. Joachim Fluhrer: "Circulating Tumour Cell assessment in Australia has been fairly new, it's not yet widely used.

Genostics® partners with world-class cancer research laboratories in Europe to bring the very best in personalised cancer testing to the Australian and New Zealand medical communities.

We engage with pioneering practitioners who seek to discover the exact nature of each patient's cancer. These practitioners use Genostics® tests to help design personalised treatment plans and to closely monitor the effectiveness of therapies.

Specialising in the field of Oncology, we are proud to be bringing the future of personalised cancer testing to patients, today.


Informative videos:

In this Genostics videocast, Dr. Joachim Fluhrer and Prof. Katharina Pachmann discuss the detection of Circulating Tumour Cells (CTCs), the metastisising populatin of cancer cells, in the blood stream.

On this Genostics videocast, Dr. Joachim Fluhrer and Prof. Katharina Pachmann discuss the relevance of Circulating Tumour Cells in the bloodstream.

In this Genostics videocast, Dr. Joachim Fluhrer and Prof. Katharina Pachmann discuss the science of Maintrac technology for counting and analysing Circulating Tumour Cells.

In this Genostics videocast, Dr. Joachim Fluhrer and Prof. Katharina Pachmann discuss the clinical utility of Maintrac Circulating Tumour Cell testing.

On this Genostics videocast, Dr. Joachim Fluhrer and Prof. Katharina Pachmann discuss the scientific validation of Maintrac CTC testing.

 

News!


August 5 2015

Your lifestyle is an on/off switch for your genes ...Find out more


June 30, 2015

Detecting the rare, renegade cancer cells ...Learn more


June 18, 2015

Survival of the fittest in cancer ...Quick read of this blog


June 8, 2015

"Even if surgery, chemotherapy, or radiation removes all traces of known cancer, there is still a risk of the cancer returning, often in a distant location in the body. This may occur as a result of CTCs."
...Read the article


June 2, 2015

Which chemotherapy kills the cells responsible for cancer spread, doctor?
...Learn more


May 18, 2015

Gene expression and the regulation of genes
...Read this article


May 11, 2015

Genetics, explained simply
...Read this blog post


May 5, 2015

What is a biomarker, and how are CTCs defined as both a biomarkers and carriers of biomarkers? ...Learn more


April 27, 2015

Circulating Tumour Cells: tell me more ...Read this article


April 20, 2014

How cancer spreads: the biology of metastasis ...Quick view


April 13 2015

DNA, Cancer, and what it takes for a cell to become cancerous ...Read this blog post


March 2015

Blog launch

We are very excited to announce the launch of the world's first Circulating Tumour Cell blog, written specifically for practitioners and their patients.


February 2015

Cancer Deconstructed

Dr. Fluhrer gives NewYou an in-depth look at the
intertwined world of cancer testing and molecular medicine.

"In what specific ways can personalised cancer testing and molecular medicine revolutionise the way people treat and think of cancer?

Every person is a separate individual, similarly every cancer is also ‘individual’ to the person affected, in a manner of speaking; cancer is heterogeneous. Cells in a malignant tumour can include cancer stem cells, promoter cells, communication cells, supportive cells, immune cells etc. Some of the cancer cells produce proteins that inhibit the immune system to recognise them and kill it." ...Read the rest of this article


December 2014

'Best of the best' publication

Prof. Pachmann's poster, outlining the use of Maintrac® technology in uncovering the heterogenous nature of Circulating Tumour Cells, was awarded 'The best of the best' poster at the Clinical Oncology Society of Australia conference. Somatic mutations of the EGFR, KRAS and BRAF genes: homogeneitiy in single cells from cell lines and heterogeneity in Circulating Epithelial Tumor Cells (CETCs) as determined using cobas® z480 analyzer (2014) ...Quick view

iStock_000007245036Medium.jpg

Patient information


SCROLL DOWN

Patient information


Every person's cancer is unique.

A growing tumour is made up of many different cancer cells. If a cancer is malignant, a select population of cancer cells can escape the tumour mass and invade the blood stream. When this happens, the cancer is at a turning point. Escapee cancer cells in the blood stream can travel to another site in the body and grow a second tumour at a later stage, called a metastasis. These escapee cancer cells in the blood are called Circulating Tumour Cells, abbreviated as ‘CTCs.’


Escapee cancer cells in the blood can be found by a simple blood test.

A CTC Count finds existing escapee CTCs in a blood sample and counts them. A CTC count every 3-6 months can be used to monitor the effectiveness of cancer treatment and assess changes in aggressiveness. This test is the best way of closely monitoring the status of a person's cancer.

A CTC Count finds existing escapee CTCs in a blood sample and counts them. A CTC count every 3-6 months can be used to monitor the effectiveness of cancer treatment and assess changes in aggressiveness. This test is the best way of closely monitoring the status of a person's cancer.

This test exposes a person's CTCs to recommended chemotherapy or botanical cancer killing agents, as selected by healthcare practitioners. This test is to see which therapy or therapy combination is most effective at killing a person's CTCs. CTCs that survive exposure are said to be resistant while CTCs that are killed by exposure are said to be sensitive. Cancer treatment can then be tailored to target the cells that are responsible for cancer spread.

This test exposes a person's CTCs to recommended chemotherapy or botanical cancer killing agents, as selected by healthcare practitioners. This test is to see which therapy or therapy combination is most effective at killing a person's CTCs. CTCs that survive exposure are said to be resistant while CTCs that are killed by exposure are said to be sensitive. Cancer treatment can then be tailored to target the cells that are responsible for cancer spread.

Companion Diagnostics identifies the presence of receptors on a person's CTCs that may be specifically targeted by certain cancer treatments. Practitioners can also choose to test for other 'biomarkers' that indicate important factors, such as aggression and activity. This test helps practitioners select treatments to target the unique nature of each person's cancer.

Companion Diagnostics identifies the presence of receptors on a person's CTCs that may be specifically targeted by certain cancer treatments. Practitioners can also choose to test for other 'biomarkers' that indicate important factors, such as aggression and activity. This test helps practitioners select treatments to target the unique nature of each person's cancer.

Tumour Sphere Units tests to see if a person's CTCS can multiply to form microscopic clusters, called Tumour Sphere Units in the laboratory. CTCs that can form clusters have stem-cell qualities, rendering them more resistant to treatment and capable of forming a second tumour, called a metastasis.

Tumour Sphere Units tests to see if a person's CTCS can multiply to form microscopic clusters, called Tumour Sphere Units in the laboratory. CTCs that can form clusters have stem-cell qualities, rendering them more resistant to treatment and capable of forming a second tumour, called a metastasis.


shutterstock_193463279.jpg

Practitioner information


SCROLL DOWN

Practitioner information


The effectiveness of cancer therapy can now be monitored

"There is increasing evidence that CTCs reflect cancer progression in real time and that this information may be particularly helpful in the context of systemic therapies. In the future, CTC characterisation is expected to contribute to guiding specific targeted therapies to a defined population of cancer patients within a certain therapeutic window...

- which is the hallmark of personalized medicine." - Clin Chem 2012